Free Trial

Xenetic Biosciences 8/13/2024 Earnings Report

Xenetic Biosciences logo
$4.14 -0.06 (-1.31%)
As of 01/30/2025 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.83
Consensus EPS
-$0.83
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.73 million
Expected Revenue
$0.54 million
Beat/Miss
Beat by +$190.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Xenetic Biosciences Inc (XBIO)
Xenetic Dips on Full-Year Results
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO), Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat